YCMGA
HUMA icon

York Capital Management Global Advisors’s Humacyte HUMA Stock Holding History

York Capital Management Global Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,399,424
Closed -$4.56M – 10
2022
Q3 		$4.56M Sell
1,399,424
-891,973
-39% -$3.42M 1.03% 7
2022
Q2 		$7.36M Hold
2,291,397
– – 2.39% 3
2022
Q1 		$16.2M Hold
2,291,397
– – 4.71% 3
2021
Q4 		$16.6M Hold
2,291,397
– – 3.7% 4
2021
Q3 		$20.6M Buy
+2,291,397
New +$26.2M 2.17% 12

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

York Capital Management Global Advisors's HUMA Position: Q4 2022 in Review

York Capital Management Global Advisors sold out of Humacyte (HUMA) in Q4 2022, closing a stake of 1,399,424 shares — an estimated $4.56M sold.

York Capital Management Global Advisors first reported a position in HUMA in Q3 2021 and held it in 5 quarters. The position peaked at $20.6M in Q3 2021. 75 funds tracked by Wall St. Rank hold HUMA as of Q4 2022.

  • York Capital Management Global Advisors reported no remaining Humacyte position as of Q4 2022 after selling out during the quarter.
  • York Capital Management Global Advisors sold 1,399,424 Humacyte shares in Q4 2022, an estimated $4.56M.
  • York Capital Management Global Advisors first reported a position in Humacyte in Q3 2021 and held it in 5 quarters.
  • York Capital Management Global Advisors's Humacyte position peaked at $20.6M in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Humacyte as of Q4 2022.

Based on York Capital Management Global Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.